(PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablet). GaviLyte-H compares to HalfLytely®* and is indicated for bowel cleansing prior to colonoscopy. GaviLyte-H is contraindicated in patients with gastrointestinal obstruction, gastric retention, bowel ...
SUPREP Bowel Prep Kit is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults
How does bowel preparation support the achievement of quality standards in colonoscopy?
Learn about Eleview™, a submucosal injection agent designed to lift polyps and keep them lifted during gastrointestinal endoscopic resection procedures.
Use with caution with medications that have a narrow therapeutic index or require rapid gastrointestinal absorption. Oral medications dependent on threshold ...
CLINIMIX sulfite-free (Amino Acid in Dextrose) Injections and CLINIMIX E sulfite-free (Amino Acid with Electrolytes in Dextrose with Calcium) Injections are indicated as a caloric component in a parenteral nutrition regimen and as the protein (nitrogen) source for offsetting nitrogen loss or for the treatment of negative nitrogen balance in patients where (1) the alimentary tract cannot or shou...
The JETPREP FLUSHING DEVICE is intended for use as a flexible endoscopic accessory to apply legally marketed solutions for washing mucosal tissue in the gastrointestinal tract.
Sodium picosulfate is converted by intestinal bacteria in the colon to an active metabolite that stimulates colonic peristalsis to effectively remove waste by emitting regular, wavelike contractions to clear the colon.2. PREPOPIK® must be stirred for 3 minutes to activate the solution.2. See How PREPOPIK® Works ...
An antisecretory antidiarrheal that: Works by normalizing water flow in the GI tract to provide symptomatic relief of diarrhea; Is not an opioid and does not affect GI motility. Minimally absorbed, well-tolerated, and proven to have: No clinically relevant drug-drug interactions
Seprafilm adhesion barrier is a medical device for adhesion prevention for patients undergoing abdominal or pelvic laparotomy. See full safety information.
Use DYLOJECT at the lowest daily dose for the shortest duration possible to minimize risk of CV, GI and hepatic adverse events. Contraindications. DYLOJECT is contraindicated in patients with: Known hypersensitivity to diclofenac or any components of the drug product. History of asthma, urticaria, or other allergic-type ...
Gastroenterology Hadjiliadis D, Khoruts A et. al.
Jan 1st, 2018 - Improved therapy has substantially increased survival of persons with cystic fibrosis (CF). But the risk of colorectal cancer (CRC) in adults with CF is 5-10 times greater compared to the general population, and 25-30 times greater in CF patients after an organ transplantation. To address this risk, the CF Foundation convened a multi-stakeholder task force to develop CRC screening recommendatio...
The Lancet. Oncology; Thuss-Patience PC, Shah MA et. al.
Mar 28th, 2017 - Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is no established therapy in the second-line setting. In GATSBY, we examined the efficacy and tolerability of trastuzumab emtansine in patients previously treated for HER2-positive advanced gastric cancer (unresectable, locally advanced, or metastatic gastric c...
Jul 2nd, 2020 - Donafenib, a deuterated derivative of sorafenib, was tested against sorafenib in the frontline setting in hepatitis B– associated hepatocellular carcinoma (HCC) in a large, multi-institutional study in China (Abstract 4506).
May 31st, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.
May 30th, 2020 - We are recapping some of the top news that have been presented during the conference—and soon we’ll speak with Dr Melissa Johnson on some of the practice-changing lung cancer data being presented, Dr Milind Javle on some pivotal gastrointestinal cancer abstracts, and Dr Hope Rugo on the biggest studies in breast cancer.
May 29th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/German trial (Abstract 11503).
Journal of Neurology, Neurosurgery, & Psychiatry; Bai. S.,et al
Oct 28th, 2019 - Objectives To systematically review the efficacy and safety of anti-inflammatory agents for patients with major depressive disorders. Methods We searched the literature to identify potentially relevant randomised controlled trials (RCTs) up to 1 January 2019. The primary outcome was efficacy, measured by mean changes in depression score from baseline to endpoint. Secondary outcomes included re...
Oct 22nd, 2019 - The ACG 2019 Annual Meeting will be held in San Antonio, Texas, at the Henry B. Gonzalez Convention Center. The Grand Hyatt San Antonio is the official ACG headquarters hotel. ACG has secured special room rates at 6 hotels in close proximity to the Convention Center.
Annals of Internal Medicine; Barkun,A.,et al
Oct 22nd, 2019 - Description: This update of the 2010 International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding (UGIB) refines previous important statements and presents new clinically relevant recommendations. Methods: An international multidisciplinary group of experts developed the recommendations. Data sources included evidence summarized in prev...